Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Other Operating Expenses (2016 - 2026)

Gyre Therapeutics has reported Other Operating Expenses over the past 11 years, most recently at -$2000.0 for Q4 2025.

  • Quarterly Other Operating Expenses fell 200.0% to -$2000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.8 million through Dec 2025, down 13.14% year-over-year, with the annual reading at -$4000.0 for FY2025, 93.94% up from the prior year.
  • Other Operating Expenses was -$2000.0 for Q4 2025 at Gyre Therapeutics, down from -$1000.0 in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $68.7 million in Q4 2021 and troughed at -$2.2 million in Q4 2023.
  • The 5-year median for Other Operating Expenses is $798000.0 (2022), against an average of $9.2 million.
  • Year-over-year, Other Operating Expenses skyrocketed 4925.9% in 2022 and then tumbled 3584.75% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $68.7 million in 2021, then crashed by 100.09% to -$59000.0 in 2022, then tumbled by 3584.75% to -$2.2 million in 2023, then surged by 100.09% to $2000.0 in 2024, then tumbled by 200.0% to -$2000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Other Operating Expenses are -$2000.0 (Q4 2025), -$1000.0 (Q3 2025), and -$1000.0 (Q2 2025).